In a study using the EZH2 inhibitor 3-deazaneplanocin A (DZNep), it was found that its treatment depleted breast carcinoma cells of the PRC2 complex members (EZH2, SUZ12, and EED),and subsequently reactivated expression of IGFBP-3 [46]. This evidence concerns the gene IGFBP3 and breast carcinoma.